Rabies remains a significant public health threat, causing approximately 59,000 deaths annually, with over 95% occurring in Asia and Africa. The Human Rabies Vaccine Market was valued at $0.62 billion in 2024 and is projected to reach $1.31 billion by 2035, exhibiting a CAGR of 6.98%. This growth is driven by increased awareness, government immunization programs, and technological advancements in vaccine development, with the route of administration playing a critical role in vaccine accessibility and efficacy.

Intramuscular (IM) injection remains the dominant route of administration, holding a 64% market share due to its long-standing acceptance, proven efficacy, and ease of use in clinical settings. The IM route is the standard for both pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) in most high-income countries. It involves injecting the vaccine into the deltoid muscle, ensuring robust systemic immune response. Its widespread adoption by healthcare professionals and incorporation into national immunization guidelines solidifies its dominant position.

Intradermal (ID) injection is the fastest-growing route, gaining significant traction, particularly in resource-limited settings and emerging markets. The ID route requires only 1/5th to 1/10th of the vaccine dose compared to the IM route, making it a highly cost-effective alternative. This dose-sparing strategy is crucial for mass vaccination campaigns in high-burden, low-income countries. While it requires more training for healthcare workers, its economic and public health benefits are driving its rapid adoption.

Do you think the intradermal route of rabies vaccination will eventually replace the intramuscular route as the global standard for PEP, or will both methods continue to coexist based on regional economic and logistical factors?

FAQ

What are the differences between intramuscular (IM) and intradermal (ID) rabies vaccination? Intramuscular (IM) administration involves injecting the vaccine into the muscle (deltoid), uses a standard dose (0.5-1.0 mL), requires 2-3 visits for PrEP or 4-5 visits for PEP, is the WHO-preferred route, and is the standard in high-income countries. Intradermal (ID) administration involves injecting into the dermis (skin), uses a reduced dose (0.1 mL, 1/5th to 1/10th of IM dose), can use a 2-visit (2-site) or 1-week (4-site) regimen for PEP, is endorsed by WHO for cost-saving, and is widely used in Asia and Africa. ID vaccination is cost-effective and allows dose-sparing, which is critical for mass campaigns, but it requires more skilled healthcare workers for proper administration and carries a higher risk of local reactions (redness, swelling).

What is the WHO-recommended post-exposure prophylaxis (PEP) regimen for rabies? The WHO recommends two PEP regimens: IM regimen (Essen regimen) — 4 doses of 0.5-1.0 mL IM on days 0, 3, 7, and 28 (day 4 dose omitted for previously vaccinated individuals), standard in North America and Europe. ID regimen (Updated Thai Red Cross regimen) — 2 doses of 0.1 mL ID on day 0 (both arms), then 1 dose on days 3, 7, and 28, or a 2-site regimen (4 visits total). The ID regimen reduces the volume of vaccine needed by up to 80%, significantly lowering costs. Both regimens must be accompanied by wound washing and rabies immunoglobulin (RIG) infiltration for category III exposures (transdermal bites or scratches).

#RabiesVaccine #IntramuscularInjection #IntradermalVaccination #PostExposureProphylaxis #GlobalHealth #WHO #RabiesPrevention